TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17379121

Group type: EXPERIMENTAL
Intervention: 3xED(95) bolus dose of cisatracurium at induction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous infusion of cisatracurium during the entire procedure
Number of subjects: 30
Study: 15661841

Group type: EXPERIMENTAL
Intervention: Glutamine 90 mM
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alanine-glucose 45:45 mM
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glutamine-glucose 45:45 mM
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (sodium chloride 308 mmol/l)
Number of subjects: 6
Study: 12039705

Group type: EXPERIMENTAL
Intervention: Pulse of insulin (0.03 U/kg s.c.) and dexamethasone (2 mg i.v.) with transient hyperglycemia
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Insulin (0.03 U/kg and 0.06 U/kg) with dexamethasone without transient hyperglycemia
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fasting with or without dexamethasone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pulse of insulin and glucose without dexamethasone
Number of subjects: 29
Study: 10534548

Group type: EXPERIMENTAL
Intervention: Steroid injection (25 mg/ml prednisolone acetate)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Local anaesthetic control
Number of subjects: 106
Study: 7597072

Group type: EXPERIMENTAL
Intervention: Didanosine added to zidovudine for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 16
Study: 1971118

Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.37 mg alprazolam
Number of subjects: 14

Group type: COMPARATOR
Intervention: 5 mg diazepam
Number of subjects: 14
Study: 394279

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (50 mg, rising to 150 mg per day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30805363

Group type: EXPERIMENTAL
Intervention: Bulk-fill composite only
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bulk-fill/Ribbond
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bulk-fill/additional Ribbond
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thermomechanical aging after restorations (BF-TMA, PRF1-TMA, PRF2-TMA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control groups (Group IN and Group IN-TMA)
Number of subjects: 80
Study: 28077587

Group type: EXPERIMENTAL
Intervention: STOP-CTX arm
Number of subjects: 500

Group type: COMPARATOR
Intervention: CTX arm
Number of subjects: 500
Study: 26053030

Group type: EXPERIMENTAL
Intervention: Atazanavir (HIV-1 protease inhibitor)
Number of subjects: 215

Group type: COMPARATOR
Intervention: NNRTI-based regimens
Number of subjects: 215
Study: 24653917

Group type: EXPERIMENTAL
Intervention: Auditory short-term training with novel stimuli (/su/ and /∫u/) for about 20 minutes.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-training group (control).
Number of subjects: 20
Study: 22193796

Group type: EXPERIMENTAL
Intervention: Antipsychotics with high risk of causing metabolic abnormalities
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: Antipsychotics with medium risk of causing metabolic abnormalities
Number of subjects: 1898

Group type: COMPARATOR
Intervention: Preexisting metabolic conditions (diabetes, hyperlipidemia, hypertension)
Number of subjects: 1898
Study: 19675533

Group type: EXPERIMENTAL
Intervention: Tryptophan challenge
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17351694

Group type: EXPERIMENTAL
Intervention: Manual therapy (twice weekly)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Stretching exercises (5 times a week)
Number of subjects: 125
Study: 15491274

Group type: EXPERIMENTAL
Intervention: Women showing cognitive balance among in-group bias, identity, and self-esteem.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pro-female bias observed in participants favoring their mothers over fathers.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sexually experienced men with positive attitudes toward sex.
Number of subjects: 0
Study: 11561239

Group type: EXPERIMENTAL
Intervention: Trapeziectomy alone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with tendon interposition
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Trapeziectomy with ligament reconstruction
Number of subjects: 67

Group type: COMPARATOR
Intervention: K-wire placement across the trapezial void
Number of subjects: 67
Study: 9029748

Group type: COMPARATOR
Intervention: Fluvoxamine (50 mg for 1 day and 100 mg for 6 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Griseofulvin (500 mg for 9 days)
Number of subjects: 12
Study: 7935655

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (400 mg/kg)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo (0.1% albumin)
Number of subjects: 255
Study: 3364221

Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions (specific interventions not detailed)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Self-efficacy beliefs
Number of subjects: 333
Study: 30461315

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 51
Study: 30423449

Group type: EXPERIMENTAL
Intervention: Peanut OIT with a maintenance dose of 125 to 250 mg peanut protein
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Peanut OIT
Number of subjects: 62
Study: 28388246

Group type: EXPERIMENTAL
Intervention: Salicylic acid peeling combined with vitamin C mesotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Salicylic acid peeling alone
Number of subjects: 50
Study: 25825393

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study: 23649189

Group type: EXPERIMENTAL
Intervention: ixabepilone 16 mg/m(2) weekly plus bevacizumab 10 mg/kg Q2W (Arm A: n = 46)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: ixabepilone 40 mg/m(2) Q3W plus bevacizumab 15 mg/kg Q3W (Arm B: n = 45)
Number of subjects: 123

Group type: COMPARATOR
Intervention: paclitaxel 90 mg/m(2) weekly plus bevacizumab 10 mg/kg Q2W (Arm C: n = 32)
Number of subjects: 123
Study: 21411446

Group type: EXPERIMENTAL
Intervention: Gefitinib plus simvastatin (GS) 250 mg/d and 40 mg/d respectively
Number of subjects: 106

Group type: COMPARATOR
Intervention: Gefitinib alone (G) 250 mg/d
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Gefitinib plus simvastatin (GS)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Gefitinib alone (G)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Gefitinib plus simvastatin (GS) in patients with wild-type EGFR nonadenocarcinomas
Number of subjects: 106

Group type: COMPARATOR
Intervention: Gefitinib alone (G) in patients with wild-type EGFR nonadenocarcinomas
Number of subjects: 106
Study: 19289454

Group type: EXPERIMENTAL
Intervention: Quetiapine plus lithium or divalproex
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo plus lithium or divalproex
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study: 17894261

Group type: EXPERIMENTAL
Intervention: Social-contextual intervention targeting fruit, vegetable, and red meat consumption, multivitamin use, and physical activity.
Number of subjects: 456
Study: 14981107

Group type: EXPERIMENTAL
Intervention: Arm A: subcutaneous interferon alfa‐2a (sc‐IFN‐alpha‐2a), subcutaneous interleukin‐2 (sc‐IL‐2), and intravenous (IV) fluorouracil
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Arm B: Arm A treatment combined with per oral 13‐cis‐retinoic acid
Number of subjects: 341

Group type: COMPARATOR
Intervention: Arm C: subcutaneous interferon alfa‐2a (sc‐IFN‐alpha‐2a) and IV vinblastine
Number of subjects: 341
Study: 11577945

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day plus Azithromycin 500 mg/day
Number of subjects: 66
Study: 9685820

Group type: EXPERIMENTAL
Intervention: iodixanol 320 mg I/ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: iomeprol 300 mg I/ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ioxaglate 320 mg I/ml
Number of subjects: 30
Study: 8015643

Group type: EXPERIMENTAL
Intervention: Levamisole (2-3 mg/kg/day) twice a week for 12 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 61
Study: 2603453

Group type: EXPERIMENTAL
Intervention: Clindamycin 900 mg q8h admixed with gentamicin 1.5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clindamycin 600 mg q6h with gentamicin 1.5 mg/kg given separately
Number of subjects: 0
Study: 811982

Group type: EXPERIMENTAL
Intervention: Prindolol (2 x 5 mg daily)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination of prindolol (2 x 5 mg) + clopamide (10 mg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 29166636

Group type: EXPERIMENTAL
Intervention: RegentK
Number of subjects: 20

Group type: COMPARATOR
Intervention: MMT (myofascial mobilization technique)
Number of subjects: 20
Study: 28807045

Group type: EXPERIMENTAL
Intervention: Best medical treatment plus renal artery stenting (stent group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Best medical treatment (BMT group)
Number of subjects: 86
Study: 25924670

Group type: EXPERIMENTAL
Intervention: Experiential Learning (EL)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Traditional Lecturing (TL)
Number of subjects: 184
Study: 22589424

Group type: EXPERIMENTAL
Intervention: Daily light smokers (3‐9 cigarettes/day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Heavier smokers (≥ 10 cigarettes/day)
Number of subjects: 131
Study: 21523384

Group type: EXPERIMENTAL
Intervention: Oily vitamin D(3) preparation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Alcoholic vitamin D(3) preparation
Number of subjects: 42
Study: 18461262

Group type: EXPERIMENTAL
Intervention: Chronic neck pain (non-traumatic, non-specific)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Whiplash-associated disorders
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chronic neck pain and whiplash-associated disorders
Number of subjects: 45
Study: 16922663

Group type: EXPERIMENTAL
Intervention: Lactose microencapsulated vitamin D(3) 100 000 IU orally at baseline, then 3 monthly (three or more doses)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (untreated subjects observed contemporaneously)
Number of subjects: 137
Study: 14500058

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (decreased caloric intake and increased physical activity)
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Control condition (diabetes support and education)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 5000
Study: 9841303

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 7626373

Group type: EXPERIMENTAL
Intervention: Hypokinetic, hyperhydrated subjects (HHS) with phosphate, fluid, and salt supplementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hypokinetic subjects (HS) without supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (exercise at 14.4 km/d)
Number of subjects: 30
Study: 2792664

Group type: EXPERIMENTAL
Intervention: Loxiglumide (0.2, 1.0, or 5.0 mg/kg.h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loxiglumide (1 or 5 mg/kg.h) with an 800-kcal meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loxiglumide (5 mg/kg.h) without caerulein or the test meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Caerulein (7.5 to 120 ng/kg.h) without loxiglumide
Number of subjects: 10

Group type: COMPARATOR
Intervention: 800-kcal meal without loxiglumide
Number of subjects: 10
Study: 653653

Group type: EXPERIMENTAL
Intervention: 20 gauge needle
Number of subjects: 99

Group type: COMPARATOR
Intervention: 22 gauge needle
Number of subjects: 99
Study: 30535357

Group type: EXPERIMENTAL
Intervention: 5-factor measurement model composed of negative affect, somatic symptoms, sleep problems, positive affect, and craving
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: 5-factor measurement model
Number of subjects: 1246
Study: 30896608

Group type: EXPERIMENTAL
Intervention: 400 IU/day of vitamin D3
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 800 IU/day of vitamin D3
Number of subjects: 50
Study: 27983887

Group type: EXPERIMENTAL
Intervention: Complete revascularisation approach
Number of subjects: 3

Group type: COMPARATOR
Intervention: PPCI of the culprit artery alone
Number of subjects: 3
Study: 24944260

Group type: EXPERIMENTAL
Intervention: Droxidopa (100-600 mg 3 times daily)
Number of subjects: 162
Study: 22517315

Group type: EXPERIMENTAL
Intervention: Promethazine (25 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Meclizine (25 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19913154

Group type: EXPERIMENTAL
Intervention: Paracervical block
Number of subjects: 72

Group type: COMPARATOR
Intervention: No local anesthesia (Control)
Number of subjects: 72
Study: 17313946

Group type: EXPERIMENTAL
Intervention: IV human albumin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15379738

Group type: EXPERIMENTAL
Intervention: Entacapone administered with 30 min delay
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Co-administered entacapone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Carbidopa/L-dopa
Number of subjects: 28
Study: 11419239

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg.kg‐1 for induction, 0.12 mg.kg‐1.h‐1 for continuous infusion)
Number of subjects: 40
Study: 9814642

Group type: EXPERIMENTAL
Intervention: Leukocyte-reduced blood transfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 0
Study: 7954541

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose combinations of different diuretics (e.g., loop diuretics with thiazides)
Number of subjects: 0
Study: 2570959

Group type: EXPERIMENTAL
Intervention: Bovine colostrum with high antibody titre against human rotavirus
Number of subjects: 120

Group type: COMPARATOR
Intervention: Artificial infant formula (control)
Number of subjects: 120
Study: 381628

Group type: EXPERIMENTAL
Intervention: Alexidine mouthwash
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo oral rinse
Number of subjects: 42
Study: 31488202

Group type: EXPERIMENTAL
Intervention: Inverse probability weighting with complete measurement of time-varying covariates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverse probability weighting with yearly measurement intervals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naive estimator ignoring time-varying confounding
Number of subjects: 0
Study: 29493523

Group type: EXPERIMENTAL
Intervention: Swedish massage combined with acupressure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Swedish massage only
Number of subjects: 40
Study: 26011141

Group type: EXPERIMENTAL
Intervention: FPHT sodium injection (400 mg PHT acid equivalent)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FPHT sodium injection
Number of subjects: 10

Group type: COMPARATOR
Intervention: PHT sodium injection (400 mg PHT acid equivalent)
Number of subjects: 10
Study: 23771848

Group type: EXPERIMENTAL
Intervention: Migraine group (n=35)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 65
Study: 21812262

Group type: EXPERIMENTAL
Intervention: Tiaohe Ganpi Recipe (TGR)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional treatment of HSCT (Control)
Number of subjects: 27
Study: 20024753

Group type: EXPERIMENTAL
Intervention: Directly Administered Antiretroviral Therapy (DAART)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Self-Administered Therapy
Number of subjects: 127
Study: 17058023

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention for weight loss through exercise and diet modification, once weekly for 16 weeks.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention
Number of subjects: 85
Study: 16516777

Group type: EXPERIMENTAL
Intervention: Sovereign with WhiteStar
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sovereign 4.0
Number of subjects: 97
Study: 14567822

Group type: EXPERIMENTAL
Intervention: Minihysteroscopy with a 3.5‐mm minihysteroscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional hysteroscopy with a 5‐mm endoscope
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Minihysteroscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional hysteroscopy
Number of subjects: 100
Study: 10588965

Group type: EXPERIMENTAL
Intervention: Synthetic human secretin (0.4 microg per kilogram of body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study: 8599309

Group type: EXPERIMENTAL
Intervention: High-fat, alcohol appetizer
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-carbohydrate appetizer
Number of subjects: 12
Study: 1851063

Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (3 pmol min‐1 kg‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (no aldosterone infusion)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Saline infusion (0.9% NaCl)
Number of subjects: 8
Study: 6794420

Group type: EXPERIMENTAL
Intervention: Metoprolol Durules 200 mg o.m.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 20
Study: 31801578

Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWHs)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 94
Study: 28302292

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg/day
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 26401704

Group type: EXPERIMENTAL
Intervention: Phenserine treatment for 12 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phenserine treatment
Number of subjects: 20
Study: 23533293

Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo nicotine patch
Number of subjects: 40
Study: 21152932

Group type: COMPARATOR
Intervention: 1 × CAF (6 mg kg(‐1) body mass caffeine, 1 h before exercise)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3 × CAF (2 mg kg(‐1) body mass caffeine on three separate occasions during the day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: PLA (0 mg caffeine)
Number of subjects: 15
Study: 19245438

Group type: EXPERIMENTAL
Intervention: PSD502 (3 actuations of spray each containing 7.5 mg lidocaine and 2.5 mg prilocaine applied 5 min before intercourse)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: PSD502
Number of subjects: 300
Study: 19124906

Group type: EXPERIMENTAL
Intervention: Morning and evening training (MEG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Evening training only (EOG)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 15158628

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 898

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Morphine (no open-label)
Number of subjects: 898
Study: 11150914

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (periCT) consisting of cyclophosphamide, epidoxorubicin, and 5-fluorouracil
Number of subjects: 197

Group type: COMPARATOR
Intervention: No perioperative chemotherapy (control)
Number of subjects: 197
Study: 9205824

Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide 0.6 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Zamifenacin 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8424420

Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg intravenously
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3319642

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide infusion
Number of subjects: 17
Study: 31464143

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone
Number of subjects: 432

Group type: COMPARATOR
Intervention: Vaginal micronized progesterone capsules
Number of subjects: 432
Study: 31000387

Group type: EXPERIMENTAL
Intervention: All-suture suture anchors (ASSAs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional suture anchors (CSAs)
Number of subjects: 14
Study: 28591776

Group type: EXPERIMENTAL
Intervention: Nonaqueous mini‐dose glucagon (MDG) (150 µg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose tablets (TABS)
Number of subjects: 20
Study: 25736954

Group type: EXPERIMENTAL
Intervention: William's training for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 23573836

Group type: EXPERIMENTAL
Intervention: Single phototherapy with reflecting curtains (SPRC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Double phototherapy (DP)
Number of subjects: 160
Study: 21740240

Group type: EXPERIMENTAL
Intervention: Filtek Silorane/Silorane adhesive (SIL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aelite LS/One‐Step Plus (AL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtek Z250/Adper Single Bond Plus (Z)
Number of subjects: 0
Study: 18261963

Group type: EXPERIMENTAL
Intervention: Dynamic plate (slotted-holes)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Static plate (fixed-holes)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both dynamic and static plates
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clinical success
Number of subjects: 66